© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 4, 291-297,
February 20, 2002
© 2002 Oxford University Press
ARTICLE |
Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer
Affiliations of authors: S. D. Ramsey, C. M. Moinpour, L. C. Lovato, J. J. Crowley, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; P. Grevstad, S. E. Rivkin, Swedish Medical Center, Tumor Institute, Seattle; C. A. Presant, St. Vincent Medical Center, Los Angeles Oncology Institute, CA; K. Kelly, University of Colorado Health Sciences Center, Denver; D. R. Gandara, University of California, Davis, Sacramento.
Correspondence to: Scott D. Ramsey, M.D., Ph.D., Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., MP-900, Box 19024, Seattle, WA 98109–1024 (e-mail: sramsey{at}fhcrc.org).
Background: It is increasingly important to have timely information about the economic impact of new cancer therapies in today's cost-conscious environment. Nearly 170 000 people are diagnosed with lung cancer annually in the United States. We performed an economic analysis alongside Southwest Oncology Group Trial S9509 to estimate the cost-effectiveness of cisplatin plus vinorelbine versus carboplatin plus paclitaxel for patients with advanced non-small-cell lung cancer. There were no statistically significant differences in survival or cancer-related quality of life between the treatment arms. Methods: Use of both protocol and nonprotocol lung cancer-related health care was tracked for 24 months from the initiation of therapy. To determine expenditures, nationally standardized costs were applied to each type of health care service used, and these were summed over time. Lifetime expenditures and 95% confidence intervals (CIs) for each arm of the trial were calculated with the use of a multivariate regression technique that accounts for censoring. Student's t tests were used to compare the difference in costs between the arms. All statistical tests were two-sided. Results: Cancer-related health care costs over the period of observation averaged $40 292 (95% CI = $36 226 to $44 359) for patients in the cisplatin plus vinorelbine arm versus $48 940 (95% CI = $44 674 to $53 208) for patients in the carboplatin plus paclitaxel arm (P = .004), with a mean difference of $8648 (95% CI = $2634 to $14 662). Protocol chemotherapy drugs and medical procedures costs were statistically significantly higher in the paclitaxel arm (P = .0003 and P<.0001, respectively), whereas protocol chemotherapy delivery costs were statistically significantly higher in the vinorelbine arm (P<.0001). There was no difference between the arms in costs for blood products, supportive care medications, nonprotocol-related inpatient or outpatient care, and nonprotocol chemotherapy. Conclusions: Treatment with carboplatin plus paclitaxel is substantially and statistically significantly more expensive than treatment with cisplatin plus vinorelbine. The majority of the cost difference is due to the additional cost of the protocol chemotherapy (approximately $12 000). Notable differences in costs of downstream health care were not apparent.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y.-C. T. Shih and M. T. Halpern Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? CA Cancer J Clin, July 1, 2008; 58(4): 231 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Warren, K. R. Yabroff, A. Meekins, M. Topor, E. B. Lamont, and M. L. Brown Evaluation of Trends in the Cost of Initial Cancer Treatment J Natl Cancer Inst, June 18, 2008; 100(12): 888 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Ganz and C. C. Gotay Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions J. Clin. Oncol., November 10, 2007; 25(32): 5063 - 5069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Azzoli, M. G. Kris, and D. G. Pfister Cisplatin Versus Carboplatin for Patients With Metastatic Non-Small-Cell Lung Cancer--An Old Rivalry Renewed J Natl Cancer Inst, June 6, 2007; 99(11): 828 - 829. [Full Text] [PDF]
|
|
|
|
|
|
R. Ng, B. Hasan, N. Mittmann, M. Florescu, F. A. Shepherd, K. Ding, C. A. Butts, Y. Cormier, G. Darling, G. D. Goss, et al. Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non-Small-Cell Lung Cancer--A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., June 1, 2007; 25(16): 2256 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vergnenegre, C. Combescure, P. Fournel, S. Bayle, C. Gimenez, P. J. Souquet, H. Lena, M. Perol, J. Y. Delhoume, and GFPC (Groupe Francais de Pneumo-Cancerologie) Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01) Ann. Onc., August 1, 2006; 17(8): 1269 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Dooms, Y. N. Lievens, and J. F. Vansteenkiste Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Eur. Respir. J., May 1, 2006; 27(5): 895 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kent, P. Korn, J. L. Port, P. C. Lee, N. K. Altorki, and R. J. Korst Cost Effectiveness of Chest Computed Tomography After Lung Cancer Resection: A Decision Analysis Model Ann. Thorac. Surg., October 1, 2005; 80(4): 1215 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Maslove, N Gower, S Spiro, R Rudd, R Stephens, and P West Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer Thorax, July 1, 2005; 60(7): 564 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Korst, H. T. Gold, M. S. Kent, J. L. Port, P. C. Lee, and N. K. Altorki Surveillance computed tomography after complete resection for non-small cell lung cancer: Results and costs J. Thorac. Cardiovasc. Surg., March 1, 2005; 129(3): 652 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Ramsey, N. Howlader, R. D. Etzioni, and B. Donato Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non-Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results-Medicare J. Clin. Oncol., December 15, 2004; 22(24): 4971 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Fryback and B. M. Craig Measuring Economic Outcomes of Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 134 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
|
|
R. Malayeri Re: Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, August 7, 2002; 94(15): 1172 - 1172. [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Roberts Jr., T. J. Lynch Jr., and B. A. Chabner Choosing Chemotherapy for Lung Cancer Based on Cost: Not Yet Oncologist, June 1, 2002; 7(3): 177 - 178. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Ramsey and L. G. Kessler Does Economics Matter When Treating Advanced Non-Small Cell Lung Cancer? Oncologist, June 1, 2002; 7(3): 179 - 180. [Full Text] [PDF]
|
|